JP2012500788A - 組成物 - Google Patents

組成物 Download PDF

Info

Publication number
JP2012500788A
JP2012500788A JP2011523454A JP2011523454A JP2012500788A JP 2012500788 A JP2012500788 A JP 2012500788A JP 2011523454 A JP2011523454 A JP 2011523454A JP 2011523454 A JP2011523454 A JP 2011523454A JP 2012500788 A JP2012500788 A JP 2012500788A
Authority
JP
Japan
Prior art keywords
docetaxel
pvp
composition
taxane
solid dispersion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011523454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012500788A5 (enExample
Inventor
ベイネン，ヤコブ，ヘンドリック
シュレンス，ヨハネス，ヘンリカス，マティアス
ムース，ヨハネス
ヌーイェン，バスティアーン
Original Assignee
スティヒティング ヘット ネーデルランド カンケル インスティテュート
スローテルファールト パーティシペィティズ ビーヴィ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2008/002854 external-priority patent/WO2009027644A2/en
Application filed by スティヒティング ヘット ネーデルランド カンケル インスティテュート, スローテルファールト パーティシペィティズ ビーヴィ filed Critical スティヒティング ヘット ネーデルランド カンケル インスティテュート
Publication of JP2012500788A publication Critical patent/JP2012500788A/ja
Publication of JP2012500788A5 publication Critical patent/JP2012500788A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011523454A 2008-08-22 2009-08-24 組成物 Pending JP2012500788A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBPCT/GB2008/002854 2008-08-22
PCT/GB2008/002854 WO2009027644A2 (en) 2007-08-24 2008-08-22 Composition
PCT/GB2009/002068 WO2010020799A2 (en) 2008-08-22 2009-08-24 Composition

Publications (2)

Publication Number Publication Date
JP2012500788A true JP2012500788A (ja) 2012-01-12
JP2012500788A5 JP2012500788A5 (enExample) 2012-10-11

Family

ID=41229935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011523454A Pending JP2012500788A (ja) 2008-08-22 2009-08-24 組成物

Country Status (3)

Country Link
EP (1) EP2328555A2 (enExample)
JP (1) JP2012500788A (enExample)
WO (1) WO2010020799A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9089544B2 (en) 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
EP2525783A1 (en) * 2010-01-18 2012-11-28 Cephalon France Improved oral lysophilisates containing pvp/va
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
CN113543781A (zh) 2018-12-21 2021-10-22 莫德拉药物股份有限责任公司 通过控制峰值血浆水平使用多西他赛的癌症治疗
EP3897611A1 (en) 2018-12-21 2021-10-27 Modra Pharmaceuticals B.V. Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor
GB202201935D0 (en) 2022-02-14 2022-03-30 Modra Pharmaceuticals B V Methods and compositions for treating cancer in taxane-resistant patients
EP4385507A1 (en) 2022-12-13 2024-06-19 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003500438A (ja) * 1999-05-27 2003-01-07 エイカスフィアー・インコーポレーテッド 多孔性薬剤マトリクスおよびその製造方法
WO2004012714A1 (en) * 2002-08-05 2004-02-12 Dsm Ip Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
US20060078619A1 (en) * 2002-11-13 2006-04-13 Hanmi Pharm Co., Ltd. Method for the preparatin of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403634B1 (en) * 1999-01-13 2002-06-11 Aventis Pharma S.A. Use of taxoid derivatives
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
AU2003256847A1 (en) * 2002-07-26 2004-02-16 Advanced Research And Technology Institute At Indiana University Method of treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003500438A (ja) * 1999-05-27 2003-01-07 エイカスフィアー・インコーポレーテッド 多孔性薬剤マトリクスおよびその製造方法
WO2004012714A1 (en) * 2002-08-05 2004-02-12 Dsm Ip Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
US20060078619A1 (en) * 2002-11-13 2006-04-13 Hanmi Pharm Co., Ltd. Method for the preparatin of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby

Also Published As

Publication number Publication date
EP2328555A2 (en) 2011-06-08
WO2010020799A3 (en) 2010-10-14
WO2010020799A2 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
US20110207804A1 (en) Compositions for the treatment of neoplastic diseases
TWI673051B (zh) 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
Sawicki et al. Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel
JP2012500788A (ja) 組成物
WO2015152433A1 (en) Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
US20230321246A1 (en) High-strength oral taxane compositions and methods
KR102512868B1 (ko) 올라파립의 용해도 및 생체이용율이 개선된 조성물
KR20160013068A (ko) 세니크리비록 조성물 및 이들을 만들고 이용하는 방법
JP2007501218A (ja) 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
Jung et al. Improved oral absorption of tacrolimus by a solid dispersion with hypromellose and sodium lauryl sulfate
Shaker Dissolution and bioavailability enhancement of Atorvastatin: Gelucire semi-solid binary system
JP2025118693A (ja) エンザルタミドを含むナノ粒子
KR102363727B1 (ko) 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법
RU2563997C2 (ru) Наночастицы оксалиплатина и способ их получения
JP6077001B2 (ja) ラパマイシン組成物
KR101441450B1 (ko) 생체 이용률이 향상된 에프로살탄 고체 분산체, 이의 제조방법 및 용도
WO2021230849A1 (en) Pharmaceutical compositions prepared by dry milling method and containing celecoxib with increased dissolution rate
KR20220077094A (ko) 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물
CA2612288A1 (en) Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US20240216347A1 (en) Bezuclastinib formulations
Neduri et al. Dissolution enhancement of lovastatin by liquisolid compact technique and study of effect of carriers
RU2830564C2 (ru) Фармацевтическая композиция для перорального введения, содержащая энзалутамид
Maraie Preparation and Evaluation of Oral Capsule-Based Niosomes for the Anti-Cancer Drug Axitinib
Sharma et al. Solubility and dissolution enhancement of water insoluble drug by using different hydrophillic carriers and formulated into tablet dosage form
WO2018156585A1 (en) Solid oral formulations of amphotericin b

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120823

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140422